FDA and EMA Collaborate on Expandable Model for Rare Pediatric Drug Development

Clinical Trials Advisor
A A
The FDA and the European Medicines Agency released a draft joint plan this month to support the development of pediatric treatments for Gaucher disease — an approach the agencies say can apply to rare diseases in general.

To View This Article:

Login

Subscribe To Clinical Trials Advisor